SR 2640 hydrochloridePotent, selective LTD4 /LTE4 receptor antagonist CAS# 146662-42-2 |
- PA-824
Catalog No.:BCC1106
CAS No.:187235-37-6
- Clofazimine
Catalog No.:BCC4651
CAS No.:2030-63-9
- 5-hydroxypyrazine-2-carboxylic acid
Catalog No.:BCC1311
CAS No.:34604-60-9
- Nitazoxanide
Catalog No.:BCC3824
CAS No.:55981-09-4
- Sodium 4-Aminosalicylate
Catalog No.:BCC4609
CAS No.:6018-19-5
- Rifapentine
Catalog No.:BCC4937
CAS No.:61379-65-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 146662-42-2 | SDF | Download SDF |
| PubChem ID | 45073453 | Appearance | Powder |
| Formula | C23H19ClN2O3 | M.Wt | 406.87 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 50 mM in DMSO | ||
| Chemical Name | 2-[3-(quinolin-2-ylmethoxy)anilino]benzoic acid;hydrochloride | ||
| SMILES | C1=CC=C2C(=C1)C=CC(=N2)COC3=CC=CC(=C3)NC4=CC=CC=C4C(=O)O.Cl | ||
| Standard InChIKey | KDSYWFCTUKABKE-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C23H18N2O3.ClH/c26-23(27)20-9-2-4-11-22(20)24-17-7-5-8-19(14-17)28-15-18-13-12-16-6-1-3-10-21(16)25-18;/h1-14,24H,15H2,(H,26,27);1H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
SR 2640 hydrochloride Dilution Calculator
SR 2640 hydrochloride Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.4578 mL | 12.2889 mL | 24.5779 mL | 49.1557 mL | 61.4447 mL |
| 5 mM | 0.4916 mL | 2.4578 mL | 4.9156 mL | 9.8311 mL | 12.2889 mL |
| 10 mM | 0.2458 mL | 1.2289 mL | 2.4578 mL | 4.9156 mL | 6.1445 mL |
| 50 mM | 0.0492 mL | 0.2458 mL | 0.4916 mL | 0.9831 mL | 1.2289 mL |
| 100 mM | 0.0246 mL | 0.1229 mL | 0.2458 mL | 0.4916 mL | 0.6144 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- H-Trp(Boc)-OH
Catalog No.:BCC3115
CAS No.:146645-63-8
- Dantrolene, sodium salt
Catalog No.:BCC6673
CAS No.:14663-23-1
- 2,6-Dimethoxybenzoic acid
Catalog No.:BCN1651
CAS No.:1466-76-8
- 2-Cyclopropyl-3-[(diphenylphosphinyl)methyl]-4-(4-fluorophenyl)quinoline
Catalog No.:BCC8572
CAS No.:146578-99-6
- Fmoc-Gly(allyl)-OH
Catalog No.:BCC3156
CAS No.:146549-21-5
- Tyrphostin AG 1296
Catalog No.:BCC1195
CAS No.:146535-11-7
- WR 1065
Catalog No.:BCC2417
CAS No.:14653-77-1
- Complanatoside A
Catalog No.:BCN6282
CAS No.:146501-37-3
- 1-Methylpsilocin
Catalog No.:BCC7536
CAS No.:1465-16-3
- Pralatrexate
Catalog No.:BCC2304
CAS No.:146464-95-1
- Camaric acid
Catalog No.:BCN1650
CAS No.:146450-83-1
- Flavopiridol
Catalog No.:BCC1577
CAS No.:146426-40-6
- (RS)-MCPG
Catalog No.:BCC6610
CAS No.:146669-29-6
- SR 11237
Catalog No.:BCC7681
CAS No.:146670-40-8
- Hybridaphniphylline A
Catalog No.:BCN7042
CAS No.:1467083-07-3
- Hybridaphniphylline B
Catalog No.:BCN7045
CAS No.:1467083-09-5
- Daphnicyclidin I
Catalog No.:BCN7038
CAS No.:1467083-10-8
- ZD 7155 hydrochloride
Catalog No.:BCC5734
CAS No.:146709-78-6
- Boc-D-Phe(4-CN)-OH
Catalog No.:BCC3183
CAS No.:146727-62-0
- N-desmethyldauricine
Catalog No.:BCC8217
CAS No.:146763-55-5
- Y-29794 oxalate
Catalog No.:BCC5795
CAS No.:146794-84-5
- 2-Bromo-1-(3-thienyl)-1-ethanone
Catalog No.:BCN2657
CAS No.:1468-82-2
- 1,5-Dihydroxyxanthone
Catalog No.:BCN7423
CAS No.:14686-65-8
- Triptobenzene H
Catalog No.:BCN6784
CAS No.:146900-55-2
LTD4 increases cytosolic free calcium and inositol phosphates in human neutrophils: inhibition by the novel LTD4 receptor antagonist, SR2640, and possible relation to modulation of chemotaxis.[Pubmed:2160189]
Agents Actions. 1990 Mar;29(3-4):299-307.
LTD4 increased the level of free intracellular calcium ([Ca++]i) and stimulated the production of inositol phosphates (IP) in human polymorphonuclear neutrophils (PMN). Calcium was predominantly mobilized from intracellular pools. After a single stimulus, the cells were refractory to a second challenge with the same concentration of LTD4, but the calcium response to LTB4 was normal. The rise in [Ca++]i as well as the stimulated production of IP was inhibited by the novel LTD4 antagonist, SR2640. SR2640 also abolished the attenuation by LTD4 of LTB4-directed PMN chemotaxis. The results suggest that human PMN contain specific LTD4 receptor that trigger phosphatidyl inositol hydrolysis by activation of phospholipase C, leading to intracellular calcium mobilization, which may be involved in modulation of chemotaxis.
Inhibition by the LTD4 antagonist, SR2640, of effects of LTD4 on canine polymorphonuclear leukocyte functions.[Pubmed:2546563]
Biochem Pharmacol. 1989 Jul 15;38(14):2291-5.
The sulfidopeptide leukotriene LTD4 selectively inhibited directed migration of canine polymorphonuclear leukocytes towards LTB4 (100 nM) with an IC50 of 38 nM. No effect on PAF-acether induced migration was observed. LTD4 did not cause detectable adherence of cells to the Boyden chamber system. Neither LTD4 nor the LTD4/LTE4 receptor antagonist, SR2640, possessed chemokinetic properties. LTD4 induced reversible aggregation of the cells with an EC50 of 36 nM. SR2640 suppressed or abolished LTD4 responses in vitro and following oral administration of the drug. SR2640 had no effect on aggregation induced by LTB4 or PAF-acether. The results can be taken as evidence that canine polymorphonuclear leukocytes possess LTD4 receptors that may be involved in a leukotriene specific micro-feedback system between the different cell types involved in inflammatory responses.
A novel leukotriene D4/E4 antagonist, SR2640 (2-[3-(2-quinolylmethoxy)phenylamino]benzoic acid).[Pubmed:2854067]
Eur J Pharmacol. 1988 Oct 11;155(1-2):117-28.
We have studied the leukotriene antagonistic activity of a novel compound, SR2640 (2-[3-(2-quinolylmethoxy)phenylamino]benzoic acid), in vitro and in vivo. SR2640 inhibited LTD4- but not histamine-induced contractions of guinea-pig ileum and trachea in a concentration-dependent manner. Schild plot analysis of tracheal LTD4 antagonism yielded a pA2 value of 8.7 and a slope not different from unity. SR2640 concentration dependently inhibited the binding of 0.4 nM [3H]LTD4 to guinea-pig lung membranes with an IC50 value of 23 nM. The curve was parallel to that of unlabelled LTD4 (IC50 = 2.2 nM). SR2640 was equally effective in antagonizing LTD4 and LTE4, but was much less potent in reducing LTC4-induced ileum contractions. In vivo, SR2640 in the dose range 0.03-1.00 mg/kg shifted the dose-response curve for guinea-pig bronchoconstriction induced by intravenous LTD4 administration to the right at a rate proportional to the dose of SR2640, without reducing the maximum attainable obstruction: the slope of the Schild plot was 0.99. SR2640 (1 mg/kg) also caused a significant inhibition of antigen-induced bronchoconstriction in anaesthetized guinea-pigs pretreated with pyrilamine, indomethacin, propranolol and suxamethonium. In conclusion, SR2640 appears to be a potent and selective competitive LTD4/LTE4 antagonist, and may be useful in elucidating the role of leukotrienes in human asthma.
